Daniel Pletzer

Senior Lecturer (Assistant Professor) @otago fighting infectious diseases and looking for alternative strategies to combat multi-drug resistant bacteria.

[Peter Fineran @PeterFineran]

New post-doctoral research position available in my Phage-host interactions (Phi) laboratory at the @otago in the Department of Microbiology and Immunology. The project is focused on defences against jumbo phages. Please share and if interested apply using the link below.

[Daniel Pletzer @pletzerlab]

@STARProtocols Fantastic to see our protocol recognized among the most notable publications in 2025 by the editors of STAR Protocols! Huge thanks to the team for their support. 🙌 Check out the protocol here: https://t.co/HFHwuXllIy

[STAR Protocols @STARProtocols]

In this special collection, the editors of STAR Protocols have compiled their selections for the most notable papers published in 2025 in their areas of expertise. Read the collection here: https://t.co/3QE8LvcX7d

[Daniel Pletzer @pletzerlab]

https://t.co/mg9xs9tjxs

[Daniel Pletzer @pletzerlab]

Lipo-peptoid TM18 disrupts P. aeruginosa and S. aureus biofilms, both individually and in co-infection. It also alleviates dermonecrosis in a murine infection model and, combined with meropenem, nearly eradicates co-infections. #AMR #biofilms #infectiousdisease #peptides

[Daniel Pletzer @pletzerlab]

Our latest study shows that the anti-biofilm peptide DJK-5 makes Staphylococcus aureus vulnerable to colistin in co-biofilms with Pseudomonas aeruginosa. A promising step in the fight against chronic co-infections! #AMR #Biofilms https://t.co/TENKPtCAS9

[Nature Microbiology @NatureMicrobiol]

OUT NOW: Bacteria use exogenous peptidoglycan as a danger signal to trigger biofilm formation

@knutdrescher @sneakystaph @biozentrum

https://t.co/srnStUfhff

[Rachel Wheatley @WheatleyRM]

Sharing three fully funded PhD opportunities to join my lab at @QUBbioscience to work on topics spanning bacterial pathogens, antibiotic resistance, microbial interactions, & mobile genetic elements. Closing dates in January and February, and open to international candidates.

[Peter Fineran @PeterFineran]

Still time to apply for travel awards to attends CRISPR 2025 in NZ

[Mark Blaskovich @mark_blaskovich]

Our open access review of antibacterial candidates with new modes of action is now officially published...now with cover image (thanks to a bit of AI help). Comprehensive analysis of those in clinical development, with an overview of promising preclinical approaches...

[Dr Jo Hobbs @Hobbs_Lab_Micro]

📢 Attention antibiotic tolerance researchers! Our GIANT review of 50+ years' of clinical antibiotic tolerance data is now available online in Clinical Microbiology Reviews. Check it out here: https://t.co/48CPcY8jL9
@ASMicrobiology @Hobbs_Lab_Micro @DeventerAshley @microclaire

[nature @Nature]

By 2050, around 2 million people — the majority aged over 70 — could die from drug-resistant infections each year https://t.co/7kQ73swYuE

[Peter Fineran @PeterFineran]

Last day to submit your application for an academic group leader position in our department in #microbiology #microbialecology #molecularmicrobiology and related areas

[Daniel Pletzer @pletzerlab]

Great times chairing the session today! :)

[Pablo Iván Nikel @pabnik.bsky.social @PabloINik]

Susanne Häussler @Rigshospitalet & Daniel Pletzer @pletzerlab chairing & opening the #antimicrobial tolerance session #Pseudomonas2024 @MicrobioSoc

[Microbiology Society @MicrobioSoc]

Welcome to the #Pseudomonas2024! We're looking forward to seeing you in Copenhagen. Over the next five days, the conference will cover the various Pseudomonas species and their role in fundamental and applied research. View the full programme online: https://t.co/WylOtsPbBK

[Microbiology and Immunology Otago @microtago]

Dr Sam Wardell from the Pletzer laboratory presented his past and present research on AMR at this week's department seminar!
Thank you for discussing your extensive work on AMR evolution in vitro and within patients, as well as combination and novel therapies!
Fantastic mahi 🦠

[Peter Fineran @PeterFineran]

I am looking for a post-doc to work on our ⁦@MBIEsci⁩ project on #phages for #biocontrol #microbiology #genomics #genetics ⁦@microtago⁩ ⁦@otago⁩ pls repost https://t.co/J7XaaJFiC0

[𝘼𝙘𝙞𝙣𝙚𝙩𝙤𝙗𝙖𝙘𝙩𝙚𝙧 𝙗𝙖𝙪𝙢𝙖𝙣𝙣𝙞𝙞 @A_baumannii]

Here our newest review we discuss Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia @docpolski @DrAnthonyKicic @MohanAmarasiri @pletzerlab @WHO @gardp_amr #amr @saveantibiotics @ABaumamee @AmrInsights @CDC_AR… https://t.co/OAt1Akeya4

[NZCRS @nz_crs]

Young Scientist Grant winner Kathy Sircombe with her poster on "Development and evaluation of controlled release responsive antibiotic delivery systems" at #CRS2024 @CRSScience @OtagoPharmacy @otago @gamble_lab

[matthew mcneil @mattmcneil86]

Couple of recent publications from our group!!

1) Awesome work from post-doc Will Jowsey showing how drug-resistance in Mtb alters tolerance to cell wall inhibitors!
https://t.co/wT3A0nXff8
(1/2)